Imidazopyrimidines, potent inhibitors of p38 MAP kinase

Kenneth C. Rupert; James R. Henry; John H. Dodd; Scott A. Wadsworth; Druie E. Cavender; Gilbert C. Olini; Bohumila Fahmy; John J. Siekierka

doi:10.1016/S0960-894X(02)01020-X

Imidazopyrimidines, potent inhibitors of p38 MAP kinase

Kenneth C. Rupert, James R. Henry, John H. Dodd, Scott A. Wadsworth, Druie E. Cavender, Gilbert C. Olini, Bohumila Fahmy, John J. Siekierka

Chemistry and Biochemistry

Research output: Contribution to journal › Article › peer-review

279 Scopus citations

Abstract

The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-α and IL-1β. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-α in vivo.

Original language	English
Pages (from-to)	347-350
Number of pages	4
Journal	Bioorganic and Medicinal Chemistry Letters
Volume	13
Issue number	3
DOIs	https://doi.org/10.1016/S0960-894X(02)01020-X
State	Published - Feb 2003

Access to Document

10.1016/S0960-894X(02)01020-X

Cite this

@article{7d7abdb3930f4329830c59775d75399d,

title = "Imidazopyrimidines, potent inhibitors of p38 MAP kinase",

abstract = "The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-α and IL-1β. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-α in vivo.",

author = "Rupert, {Kenneth C.} and Henry, {James R.} and Dodd, {John H.} and Wadsworth, {Scott A.} and Cavender, {Druie E.} and Olini, {Gilbert C.} and Bohumila Fahmy and Siekierka, {John J.}",

year = "2003",

month = feb,

doi = "10.1016/S0960-894X(02)01020-X",

language = "English",

volume = "13",

pages = "347--350",

journal = "Bioorganic and Medicinal Chemistry Letters",

issn = "0960-894X",

publisher = "Elsevier Ltd",

number = "3",

}

TY - JOUR

T1 - Imidazopyrimidines, potent inhibitors of p38 MAP kinase

AU - Rupert, Kenneth C.

AU - Henry, James R.

AU - Dodd, John H.

AU - Wadsworth, Scott A.

AU - Cavender, Druie E.

AU - Olini, Gilbert C.

AU - Fahmy, Bohumila

AU - Siekierka, John J.

PY - 2003/2

Y1 - 2003/2

N2 - The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-α and IL-1β. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-α in vivo.

AB - The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-α and IL-1β. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-α in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0037330356&partnerID=8YFLogxK

U2 - 10.1016/S0960-894X(02)01020-X

DO - 10.1016/S0960-894X(02)01020-X

M3 - Article

C2 - 12565927

AN - SCOPUS:0037330356

SN - 0960-894X

VL - 13

SP - 347

EP - 350

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

IS - 3

ER -

Imidazopyrimidines, potent inhibitors of p38 MAP kinase

Abstract

Access to Document

Other files and links

Fingerprint

Cite this